弱视临床试验与实践测量结果:改善空间——第77届Edward Jackson纪念讲座
该讲座综述随机研究和IRIS登记数据,指出临床试验通过减少遮盖时长和阿托品滴眼频率将弱视治疗负担降低且成功率约83%,但临床实践中各年龄段和种族仍存在残余视力损害,少数族裔成功率更低。
要点
- 临床试验显示弱视治疗成功约83%,且减少遮盖和滴眼频率。
- IRIS登记弱视患病率2.47%,屈光不正占儿童病例68.9%。
- 3-7岁儿童IRIS-50成功率77.3%,非裔和西班牙裔成功率显著更低。
核心结论
- 临床试验证明多种弱视治疗有效且剂量较既往推荐大幅降低,但临床实践中各年龄和种族仍有残余视力损害,少数族裔更明显。
研究设计与样本
- 综述已发表研究、分析2013至2019年IRIS登记数据及IRIS-50视力质量指标,并结合个人观点。
主要发现
- 临床试验使弱视治疗负担降低,成功率约83%,5岁前治疗无明显年龄效应,疗效稳定至少至15岁,至12岁仍有一定效果。
- IRIS登记识别1,760,066例弱视个体,患病率2.47%,单纯屈光不正占儿童病例68.9%。
- 3-6岁儿童弱视眼视力平均提高1.8行,7-12岁提高0.8行,但平均残余弱视超过2行。
- 3-7岁适合IRIS-50的18,841名儿童中77.3%成功。
- 非裔美国儿童(OR 0.67;95%CI 0.58-0.78)和西班牙裔或拉丁裔儿童(OR 0.84;95%CI 0.75-0.94)成功 odds 显著低于白人儿童。
关键数值与推荐
- 临床试验中弱视治疗临床成功率约83%。
- IRIS登记弱视患病率2.47%。
- 单纯屈光不正占儿童弱视病例68.9%。
- 3-7岁儿童IRIS-50成功率为77.3%。
- 非裔美国儿童成功OR 0.67(95%CI 0.58-0.78),西班牙裔或拉丁裔儿童OR 0.84(95%CI 0.75-0.94)。
临床怎么用
- 临床可参考临床试验证据减少遮盖时长和阿托品滴眼频率以降低治疗负担。
- 应关注临床实践中各年龄段和种族残余视力损害,尤其少数族裔儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe amblyopia prevalence and outcomes using results from randomized studies and a clinical registry. DESIGN: Review of published studies, analysis of data in Intelligent Research in Sight (IRIS) Registry from 2013 to 2019, personal perspective. METHODS: Literature review, analysis of IRIS Registry data and IRIS-50, a visual acuity quality measure. RESULTS: Clinical trials have reduced the treatment burden of amblyopia by reducing hours of patching and frequency of atropine eye drops with clinical success of about 83%. There is no appreciable age effect if treatment is started before 5 years of age, outcomes are stable to at least 15 years of age, and treatment can be somewhat effective until 12 years of age. The IRIS Registry identified 1,760,066 individuals with amblyopia for a prevalence of 2.47%. Refractive error alone accounted for 68.9% of childhood cases. Mean amblyopic eye visual acuity improved 1.8 lines for children 3-6 years of age and 0.8 lines for 7-12 years, but mean residual amblyopia was more than 2 lines. Among 18,841 children aged 3-7 years eligible for IRIS-50, 77.3% were successful. The odds ratios for success were significantly lower for African-American (0.67; 95% confidence interval [CI] = 0.58 to 0.78) and Hispanic or Latino (0.84; 95% CI = 0.75 to 0.94) children compared with white children. CONCLUSIONS: Clinical trials provided evidence of a beneficial effect from several treatments, with substantially reduced doses than previously recommended. Registry data from clinical practice found residual visual acuity impairment among all ages and races, especially among minorities.
引用
- Repka MX. Amblyopia Outcomes Through Clinical Trials and Practice Measurement: Room for Improvement: The LXXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2020. PMID: 32777377. doi:10.1016/j.ajo.2020.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。